+ND Capital logo

+ND Capital

North America, California, United States, San Mateo

Description

+ND Capital, formerly known as NanoDimension, is a prominent venture capital firm based in San Mateo, California, with a distinct focus on disruptive technologies. The firm specializes in investments at the convergence of the life and physical sciences, targeting innovations that promise significant societal and economic impact. Their investment thesis centers on deep technology, encompassing a broad spectrum of sectors including biotechnology, medtech, diagnostics, digital health within life sciences, and advanced materials, quantum computing, artificial intelligence, robotics, and climate tech within physical sciences. This dual-pronged approach allows +ND Capital to identify and nurture groundbreaking companies that often bridge traditional scientific disciplines.

The firm typically acts as the first institutional investor, engaging with companies from the seed stage through Series B rounds. This early-stage commitment underscores their belief in long-term partnerships and their willingness to provide foundational capital to nascent ventures. +ND Capital is known for its hands-on approach, leveraging the extensive scientific and entrepreneurial expertise of its team to support portfolio companies beyond just capital injection. They aim to help founders navigate the complex journey from scientific discovery to market-ready products, emphasizing robust intellectual property and scalable business models.

Financially, +ND Capital has demonstrated significant fundraising capabilities, reflecting investor confidence in their strategy and execution. For instance, the firm successfully closed its Fund IV in March 2022, securing $350 million in commitments. Prior to this, their Fund III closed at $250 million in 2018, illustrating a consistent growth in their capital base. When it comes to initial investments, +ND Capital typically deploys first checks ranging from $1 million to $10 million. This initial investment range is complemented by substantial reserves earmarked for follow-on investments, ensuring that promising portfolio companies receive continued support as they achieve milestones and scale their operations. Their strategy is to build a concentrated portfolio of high-potential ventures, providing them with the necessary resources to achieve commercial success and drive technological advancement.

Investor Profile

+ND Capital has backed more than 56 startups, with 6 new investments in the last 12 months alone. The firm has led 14 rounds, about 25% of its total and boasts 12 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B, Series C, Series A rounds (top funding stages).
  • Majority of deals are located in United States, Switzerland, United Kingdom.
  • Strong thematic focus on Biotechnology, Health Care, Medical.
  • Led 1 rounds in the past year.
  • Typical check size: $1M – $10M.

Stage Focus

  • Series B (25%)
  • Series C (23%)
  • Series A (18%)
  • Series D (13%)
  • Series Unknown (11%)
  • Seed (5%)
  • Series E (4%)
  • Private Equity (2%)

Country Focus

  • United States (82%)
  • Switzerland (9%)
  • United Kingdom (4%)
  • Denmark (4%)
  • France (2%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Life Science
  • Software
  • Therapeutics
  • Pharmaceutical
  • Semiconductor
  • Artificial Intelligence (Ai)
  • Electronics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does +ND Capital frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 6
Google Ventures
North America, California, United States, Mountain View
Co-Investments: 4
Paladin Capital Group
North America, District of Columbia, United States, Washington
Co-Investments: 9
Polaris Partners
North America, Massachusetts, United States, Boston
Co-Investments: 8
Illumina Ventures
North America, California, United States, Foster City
Co-Investments: 4
Foresite Capital
North America, California, United States, San Francisco
Co-Investments: 6
Mérieux Equity Partners
Europe, Rhone-Alpes, France, Lyon
Co-Investments: 5
Flagship Pioneering
North America, Massachusetts, United States, Cambridge
Co-Investments: 10
ARCH Venture Partners
North America, Illinois, United States, Chicago
Co-Investments: 9
Fidelity
North America, Massachusetts, United States, Boston
Co-Investments: 4

Which angels does +ND Capital often collaborate with?

JD
North America, California, United States, Menlo Park
Shared Deals: 1
JP
North America, California, United States, San Francisco
Shared Deals: 1
TA
North America, Massachusetts, United States, Cambridge
Shared Deals: 1
BN
North America, Massachusetts, United States, Boston
Shared Deals: 1
LT
North America, California, United States, San Jose
Shared Deals: 1
FB
North America, New York, United States, New York
Shared Deals: 1
SH
North America, California, United States, Santa Monica
Shared Deals: 1
Shared Deals: 1
JM
North America, Massachusetts, United States, Cambridge
Shared Deals: 1

What are some of recent deals done by +ND Capital?

Visby Medical

San Jose, California, United States

Visby Medical is a diagnostics company that develops polymerase chain reaction diagnostic tests for the detection of infectious diseases.

Health CareHealth DiagnosticsMedical
Series UnknownJun 17, 2025
Amount Raised: $55,000,000
HAYA Therapeutics

Lausanne, Vaud, Switzerland

HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome.

BiotechnologyGeneticsHealth CareMedicalTherapeutics
Series AMay 8, 2025
Amount Raised: $65,000,000
AIRNA

Cambridge, Massachusetts, United States

AIRNA develops RNA editing technologies to create medicines for various diseases.

BiotechnologyHealth CareMedical
Series BApr 1, 2025
Amount Raised: $155,000,000
Constructive Bio

Cambridge, Cambridgeshire, United Kingdom

At Constructive Bio we rewrite genomes to build the biomolecules of the future.

Biotechnology
Series ASep 24, 2024
Amount Raised: $57,735,480
Vandria

Lausanne, Vaud, Switzerland

Vandria creates mitophagy inducers that renew cells to address ageing and chronic disorders.

ManufacturingPharmaceutical
Series AAug 21, 2024
Amount Raised: $10,100,000
AIRNA

Cambridge, Massachusetts, United States

AIRNA is a biotech company that is pioneering RNA editing therapies to improve the health of individuals.

BiotechnologyHealth CareMedical
Series AJul 31, 2024
Amount Raised: $60,000,000
PulseSight Therapeutics

Paris, Ile-de-France, France

PulseSight Therapeutics creates innovative non-viral gene therapies using minimally invasive delivery technology.

BiotechnologyMedicalTherapeutics
SeedFeb 28, 2024
Partillion Bioscience

Los Angeles, California, United States

Partillion Bioscience is an early-stage life science company developing a functional single-cell analysis platform.

BiotechnologyHealth CareMedicalService Industry
SeedSep 26, 2023
Amount Raised: $5,000,000
Notify Therapeutics

Copenhagen, Hovedstaden, Denmark

Notify Therapeutics develops therapies for the treatment of infertility.

BiotechnologyLife ScienceMedicalTherapeutics
Series UnknownSep 25, 2023
Amount Raised: $5,295,713
H55

Sion, Valais, Switzerland

H 55 is developing certified technology solutions to make aviation clean, quite, efficient, affordable and ultimative autonomous.

AerospaceElectronicsManufacturing
Series CSep 21, 2023
Amount Raised: $49,739,586